Description
An orally active, potent p38 MAPK inhibitor that potently inhibits ex vivo LPS" induced TNFalpha secretion with an IC50 of 44 ng/mL (115nM); inhibits LPS" stimulated TNFalpha release in the human whole blood assay with IC50 of 24nM; shows anti-inflammatory activity for treatment of acute as opposed to chronic inflammation disorders. COPD Phase 1 Clinical